Recently, medicine including cetuximab, an anti-EGFR, and pembrolizumab, an anti-PD-1 therapy, was accepted for late-stage, recurrent, or metastatic HNSCC [33,34]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.